Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate's Bipartisan Rx Pricing Probe Seeks Documents Regarding FDA Regs

This article was originally published in The Pink Sheet Daily

Executive Summary

Probe launched by the Senate Aging panel asks four manufacturers – Valeant, Turing, Retrophin and Rodelis – for documents pertaining to pricing their products, but also wants to know how they may have analyzed FDA regs to help them avoid competition.


Related Content

Valeant Discounts Will Save Health Care System $600M Annually, Firm Says
FDA Priority Review For Some Generics Urged To Address 'Market Failure'
Mylan Joins Firms Facing DOJ Probe On Price Hikes; Senate Plans Industry-Free Hearing
Express Scripts Turns To Compounding To Fight High-Priced Off-Patent Drugs
HHS Raises Profile In Drug Costs Discussion
PhRMA Takes Aim At Valeant In Defense Of Drug Pricing By ‘Innovative’ Firms
Congressional Dems Generating Heat, But No Hearings, On Rx Prices


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts